PHILLIPS CONSULTING GROUP, LLC
|
|
- Olivia Francis
- 6 years ago
- Views:
Transcription
1 Premarket Notification: A Key Element of US Medical Device Regulation Presented by Philip J. Phillips IOM Workshop Public Health Effectiveness of the FDA 510(k) Clearance Process Washington, D.C., June 14, 2010
2 Goals 1. Provide objective information on today s 510(k) program on which IOM can draw conclusions and formulate recommendations 2. Ensure that the complexities of the regulatory system are not overlooked in the process 3. Contribute to regulatory reform that results in reasonable premarket review that encourages innovation, promotes and protects public health and achieves an optimum premarket/postmarket balance 2
3 Outline I. The Breadth of FDA Responsibility II. Safety & Effectiveness III. Device Classification IV. Premarket Notification a. Substantial equivalence b. Scientific integrity of the process c. Strengths, weaknesses and flexibilities V. Comparison: 510(k) v. PMA VI. Environmental Considerations VII. Closing Remarks 3
4 The Breadth of FDA Responsibility Not merely tongue depressors to implantable defibrillators General purpose articles Device components, parts and accessories Custom devices Devices resulting from - Reprocessing of OEM single use disposable devices - Remanufacturing of durable medical equipment The system of identifying generic types of devices and classifying them is an efficient means to allocate FDA resources and maximize FDA s impact on public health. 4
5 Safety & Effectiveness Considerations Intended patient population Conditions of use in labeling or advertising Balance of health benefits to risks from use Reliability of the device Reasonable assurance of safety Probable benefits derived from use outweigh probable risks; and absence of unreasonable risk of illness or injury Reasonable assurance of effectiveness 5 Clinically significant results in a significant portion of the target population
6 Foundation for Premarket Notification The approach to assuring S&E varies by the particular device s classification Classification determines the nature and degree of FDA regulation Class I (general controls) Class II (performance standards/special controls) Class III (premarket approval) Premarket notification (510(K)) is the general control that determines the classification of new devices 6
7 Classification - Generic Type of Device Generic type of device means a grouping of devices that do not differ significantly in purpose, design, materials, energy source, function, or any other feature related to safety and effectiveness, and for which similar regulatory controls are sufficient to provide reasonable assurance of safety and effectiveness. Currently there are >1800 generic types of devices that are the subjects of classification regulations 7
8 The Formation of Today s 510(k) Program Initial comparisons were easy; little apparent differences between the old and new Concept of SE was quickly challenged Mandatory performance standards could not be developed for class II devices Differences between new and old became more pronounced (intended use and technology) Any measurable shift toward PMA process threatened to drain FDA resources SE evolved to compensate for regulatory realities 8
9 Substantial Equivalence A device is substantially equivalent if, in comparison to a predicate, it: has the same intended use as the predicate; and has the same technological characteristics as the predicate; or has the same intended use as the predicate; and has different technological characteristics and the information submitted to FDA; - does not raise new questions of safety and effectiveness; and - demonstrates that the device is at least as safe and effective as the legally marketed device. 9
10 The Meaning of Intended Use Refers to the objective intent of the persons legally responsible for the labeling of devices (21 CFR 801.4) defined for postmarket purposes, not 510(k) In the context of 510(k), the scope is narrower Aspects of intended use of significance include the indications for use, Rx v. OTC distribution and whether the device is for reuse v. SUD Changes in indications for use - Present the biggest regulatory challenges - Agency decisions are the most difficult to explain 10
11 Intended Use (continued) For PMA devices, indications for use refers to the disease or condition, including the patient population for which it is intended For 510(k) devices, indications for use may also be functional in nature, i.e., what the device does Changes in indications for use, 2 varieties - Expansions in patient population e.g., cardiovascular diagnostic catheters proposed for cardiac ablation procedures - General to specific use (or vice versa) e.g., CO2 lasers labeled for photocoagulation, cutting and ablation of soft tissue proposed for tattoo removal 11
12 Intended Use (continued) Our recommendation: consider the following definition to understand FDA s 510(k) approach to intended use In the context of 510(k), intended use is a regulatory concept that determines the boundaries of use for a generic type of device and is constructed to encompass the widest breadth of use where the regulatory controls for the device type continue to assure S&E. 12
13 Lumenis, Ltd. C02 Laser (K100415) Cleared April 14, 2010 for vaporization, incision, excision, ablation or photocoagulation of soft tissue in 9 surgical specialties Let s examine one specialty area: Dermatology The AcuPulose laser is indicated for use in dermatorlogy and plastic surgery for the following applications: Ablation, vaporization, excision, incision, and coagulation of soft tissue in the performance of : Laser skin resurfacing Laser dermabrasion Laser burn debridement Laser skin resurfacing (ablation and/or vaporization) for the treatment of : wrinkles, rhytids and furrrows (including fine lines and texture irregularities). Laser skin resurfacing (ablation, and/or vaporization) of soft tissue for the reduction, removal, and/or treatment of: - Keratoses, including actinic and seborrheic keratosis, seborrhoecae vulgares, sebborhecfi wart and verrut seborrheica - Vermillionectomy of the lip - Cutaneous horns - Solar/actinic elastosis - Cheilitis, including actinic cheilitis - Lentigines, including lentigo maligna or Hutchinson s malignant freckle - Uneven pigmenmtation/dyschromia - Acne scars - Surgical scars - Keloids, including acne keloidalis nuchae 13 - Hemangiomas (including Buccal, port wine, a d pyonenic granulomas/granuloma pyogenicum/granuloma telangiectaticum) - Tatoos - Telangiectasia - Removal of small skin tumors, including periungual (Koenen) and subungual fibromas - Superficial pigmented lesions - Adenosebaceous hypertrophy and sebaccrous hyperplasia - Rhinophyma reduction - Cutaneous papilloma (skin tags) - Milia - Debridement of eczematous or infected skin - Bramous and squamous cell carcinoma, including keratoacanthomas, Bowen s disease (Erythroplasia of Queyrat), and Bowenoid Papulosis (BP) lesions - Nevi, including spider, epidermal, and protruding - Neurofibromas - Laser de-epitheliazation - Tricoepitheliomas - Xanthelasma palpebrarum - Syringoma Laser ablation, vaporization, and/or excision for complete and partial nail matrixecomy Vaporization/coagulation of: - Benign.malignant vascular/avascularskin lesions - Moh s surgery - Lipectomy - Verrucae and seborrhoecae, vulgaris, including paronychial,, perungal and subungal warts Laser incision and/or excision of soft tissue for the performance of upper and lower eyelid blepharoplasty Laser incision and/or excision of soft tissue for the creation of recipient sites for hair transplantation
14 Technological Characteristics FDA s approach to differences in technology 1. Do the differences raise new safety or effectiveness questions? - If yes, device is NSE - FDA interprets as new types of safety and effectiveness questions to afford agency discretion in decision-making 2. Is the new device as safe and effective as the existing? - FDA asks, Can the risks inherent with the new technology be mitigated? - Note: This is not a S&E evaluation similar to PMA Example Wireless telemetry Technology poses no new types of S&E questions Performance testing and labeling requirements mitigate risks 14
15 Scientific Integrity of 510(k) For a new device having the same intended use and the same technological characteristics Descriptive data - all cases - Side-by-side comparison of designs with specifications Performance data -when descriptive data does not assure performance - e.g., biocompatibility of patient contacting materials (ISO 10993) and electrical safety (IEC 60601) For a new device with differences in intended use and technological characteristics 15 As above, plus performance data (bench, animal and clinical) to assess the differences and mitigate associated risks
16 Scientific Integrity of 510(k) (continued) New devices include devices that are modified by their manufacturers With devices, constant and rapid change is inevitable Major changes in intended use/device design changes that could significant affect S&E require FDA clearance; subject to the same scientific review standards Manufacturers must decide what changes require a new clearance within the confines of their quality system Integrity of the 510(k) process requires 1.verifying necessary submissions are filed; and 2.that all changes have undergone proper V/V 16
17 510(k): Strengths Weaknesses and Flexibilities Strengths Flexibility, e.g., freedom to apply knowledge from precedent Ability to grant exemptions (adjust agency priorities) Weaknesses Lack of device specific guidance and special controls Ability to address S&E issues with cleared devices Flexibilities 17 Opportunity to request needed information Ability to leverage the work of SDOs through the recognition of consensus standards for use in review 3 rd party review
18 Premarket Notification v. Approval First programs should not be compared 510(k) is a classification process PMA is a determination of S&E that leads to approval 510(k) Class I and II Substantial Equivalence S&E N.A. [S&E requires verification and vigilance] Unconditional Clearance Class III PMA Reasonable assurance of S&E S&E device-by-device, premarket conformance assessment Conditions for the TPLC FDA Approval 18
19 Environmental Considerations Competition, cost containment and the practice of medicine Environment factors prompt device differentiation Intended use and technology provide the means The result -regulatory challenges - Combination products (devices, drugs and biologics) - Software control, networked systems and inter-device compatibility - Issues with the device user interface (human factors) - IVD Multivariate Index Assays (IVDMIAs) - Reuse of SUDs FDA s regulatory system should anticipate change and promote product improvement 19
20 Closing Remarks Assuring that devices are safe and effective is a complex system of requirements, with 510(k) being one component The 510(k) process differs from how it is most frequently characterized concept of SE is misleading The 510(k) program has strengths and weaknesses, but it makes significant contributions to public health. Whether 510(k) is maintained as is, changed or abandoned, the system must be flexible enough to accommodate constant and rapid change, and have the integrity to withstand criticism; For FDA staff, making correct decisions is difficult enough without having the underlying regulatory process constantly under attack. 20
The New Standard in Laser Surgery
The New Standard in Laser Surgery Perform at a Higher Level Alma Lasers' CO 2 is a high powered surgical laser that brings unparalleled precision and innovation to the surgical field. Supporting a wide
More informationBEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018
BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE Yuan Xu 18- JAN- 2018 Background AGENDA What is Medical Device? What is 510(k)? Principles of best practices of device
More informationBe an artist of the new
Be an artist of the new era. Dynamis Highest Performance Er:YAG and Nd:YAG Laser System Additional Surgical QCW Nd:YAG Laser Capability Complete Inside-to-Out Treatments Easy-to-Use Treatment Parameter
More information510(k) Premarket Notification Database
FDA > CDRH > 510(k) Premarket Notification Database Search http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?i... New Search Back To Search Results 510(k) Premarket Notification Database
More informationLUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT
LUMPS AND BUMPS: AN ORGANIZED APPROACH TO DIAGNOSIS AND MANAGEMENT Tammy P. Than, M.S., O.D., F.A.A.O. The University of Alabama at Birmingham / School of Optometry 1716 University Blvd. Birmingham, AL
More informationSKIN LESIONS. On behalf of Airedale, Wharfedale and Craven CCG, Bradford City CCG and Bradford Districts CCG. Bradford and Airedale CCGs.
Bradford and Airedale CCGs SKIN LESIONS Version: 2 Ratified by: Date ratified: Author(s): Responsible Committee: Consultant in Public Health Individual Funding Request Panel Date issue: September 2013
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationTobacco Product Applications: FDA Perspective
Tobacco Product Applications: FDA Perspective Matthew R. Holman, Ph.D. Director, Office of Science Center for Tobacco Products Disclaimer: This information is not a formal dissemination of information
More informationPreparing a US FDA Medical Device 510(K) Submission
Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via
More informationFDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC
AIPLA Annual Meeting Joint Biotechnology Committee/ Special Committee on FDA Law Program October 21, 2010 Marriott Wardman Park Hotel Washington, DC FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs
More informationU.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. Preface
U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Preface Public Comment: The Food and Drug Administration (FDA) is announcing the availability
More informationCONDITIONS OF THE SKIN
CONDITIONS OF THE SKIN UCSF/SFGH Family & Community Medicine Residency Program Educational Objectives I. Knowledge The resident will be able to discuss the definition, diagnosis, and initial management
More informationBenign Skin Lesions and Cosmetic Treatments Criteria Based Access Protocol Supporting people in Dorset to lead healthier lives
NHS Dorset Clinical Commissioning Group Benign Skin Lesions and Cosmetic Treatments Criteria Based Access Protocol Supporting people in Dorset to lead healthier lives 1. INTRODUCTION AND SCOPE NHS DORSET
More informationMedical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years. Written Statement of
Medical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years Written Statement of Dr. David R. Challoner Vice President for Health Affairs, Emeritus University of Florida and Chair,
More informationCenter for Devices & Radiological Health: Lifecycle Products. Laura Marquart, MD, FAAD
Center for Devices & Radiological Health: Lifecycle Products Laura Marquart, MD, FAAD 1 AAD FDA Symposium: Medical Devices The intent of this presentation is to present in brief specific actions by FDA
More informationPosition Statement Treatments that primarily affect the appearance are considered medically necessary only in the following circumstances:
Policy Name: Cosmetic Services Policy Number: CMO 500 Effective Date of current policy: 9/1/2018 Description and Scope This policy applies to procedures that primarily affect the appearance of the member.
More informationFDA 510(k) 101 The Basics
FDA 510(k) 101 The Basics Floyd G. Larson President, PaxMed International San Diego, CA OMTEC June 17, 2010 Chicago Agenda History of 510(k) process FDA s risk based approach FDA guidance and standards
More informationPremalignant skin tumours
Chapter 14: Premalignant skin tumours page: 434 Premalignant skin tumours page: 435 Solar keratoses (senile keratoses) Raised red and well-defined plaques with a rough surface covered in scales of varying
More informationIntegumentary system pertains to the skin, subcutaneous tissue and areolar tissue.
TRICARE/CHAMPUS POLICY MANUAL 6010.47-M DEC 1998 Surgery And Related Services CHAPTER 3 SECTION 2.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) I. PROCEDURE CODE RANGE 10040-19499
More informationSPECIALISED SERVICES POLICY: CP 42 TREATMENT OF BENIGN SKIN CONDITIONS
SPECIALISED SERVICES POLICY: CP 42 TREATMENT OF BENIGN SKIN CONDITIONS Document Author: Specialised Planner Executive Lead: Director of Planning Approved by: Management Group Issue Date: 11 July 2013 Review
More informationMCL31 Dermablate THE WORLD S MOST SUCCESSFUL ERBIUM:YAG LASER FOR AESTHETIC MEDICINE
MCL31 Dermablate THE WORLD S MOST SUCCESSFUL ERBIUM:YAG LASER FOR AESTHETIC MEDICINE POWERFUL effective S A F E TREATMENT OF DERMAL AND EPIDERMAL LESIONS The MCL31 Dermablate allows for performing ablations
More informationLIGHT SERIES MULTIPLE WAVELENGTHS FOR THE HIGHEST CHALLENGES IN LASER APPLICATIONS
LIGHT SERIES MULTIPLE WAVELENGTHS FOR THE HIGHEST CHALLENGES IN LASER APPLICATIONS ALEXANDRITE 755nm 1064nm 532nm 1320nm 1 TAKING CARE OF PEOPLE, OUR MASTERPIECES Quanta System was born in 1985 as a spin-off
More informationIndex. B Bacterial infections, prevention of, in laser therapy, 183, 208, 209, 224, 290. Note: Page numbers of article titles are in boldface type.
Oral Maxillofacial Surg Clin N Am 16 (2004) 301 307 Index Note: Page numbers of article titles are in boldface type. A Acne, laser skin resurfacing and, 295 296 Actinic keratoses, carbon dioxide laser
More informationRegulatory Submission Strategies and Outlines For Ultrasonic Surgical Devices: Contact and HIFU Systems UIA Symposium Ronald R.
Regulatory Submission Strategies and Outlines For Ultrasonic Surgical Devices: Contact and HIFU Systems 2006 UIA Symposium Ronald R. Manna Regulation Governing Medical Devices Europe: Council Directive
More informationClass II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA
Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the
More informationFDA issues long-awaited final guidance on when a device modification requires a new 510(k)
FDA issues long-awaited final guidance on when a device modification requires a new 510(k) November 2, 2017 Six years after its first attempt to update its 20-year-old guidelines for when modifications
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More informationOverview of the Legal Framework for Medical Device Regulation in the United States
1 Overview of the Legal Framework for Medical Device Regulation in the United States Ellen J. Flannery This chapter provides an overview of the legal framework for medical device regulation in the United
More informationSeptember 28, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
September 28, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. : Center for Devices and Radiological Health 510(k)
More informationNEURONETICS. 510(k) SUMMARY NEUROSTAR TMS THERAPY SYSTEM'
NEURONETICS 510(k) SUMMARY NEUROSTAR TMS THERAPY SYSTEM' 510(k) Owner: Neuronetics, Inc. DEC 1 6 Z008 1 Great Valley Parkway, Suite 2 Malvern, PA 19355 Phone: 610-640-4202 Fax: 610-640-4206 Company Contact:
More informationFDA s 510(k) Working Group
Understing the Premarket Notification (510(k)) Process FDA s 510(k) Working Group Presentation to the Institute of Medicine March 1, 2010 Donna-Bea Tillman, Ph.D. Director, Office of Deice Ealuation U.S.
More informationIn Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review
In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review Cardiac Safety Research Consortium December 3, 2015 Lea Carrington Division of Immunology and Hematology Devices Office of In
More informationPrimer: Medical Device User Fee Amendments Han Zhong l September 2011
Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration
More informationCLINICAL EVALUATION REPORT ON THE EFFICACY AND SAFETY OF THE CORE SYSTEM FOR FACIAL ENHANCEMENT TREATMENTS
CLINICAL EVALUATION REPORT ON THE EFFICACY AND SAFETY OF THE CORE SYSTEM FOR FACIAL ENHANCEMENT TREATMENTS BACKGROUND Efforts to improve fractional ablative laser systems have led to the development of
More informationName of Policy: Pulsed Dye Laser Treatment of Recalcitrant Verrucae
Name of Policy: Pulsed Dye Laser Treatment of Recalcitrant Verrucae Policy #: 187 Latest Review Date: July 2010 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature
More informationATTACHMENT A AdvaMed Comments Draft-Guidance for Industry and FDA Staff -510(k) Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device Line(s) No. Line or lines numbers of the
More informationDEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND
DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND 20889-5600 04 October 2016 MEMORANDUM FOR DERMATOLOGY CLINIC PERSONNEL SUBJECT: Standard Operating Procedure for
More informationThe proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.
ADVISORY Food & Drug FDA ISSUES PROPOSED RULE TO ESTABLISH A UNIQUE DEVICE IDENTIFICATION SYSTEM FOR MEDICAL DEVICES July 16, 2012 On July 11, 2012, the Food and Drug Administration (FDA) published in
More information510(k) submissions. Getting US FDA clearance for your device: Improving
Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white
More informationFebruary 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040
February 15, 2018 AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 Re: K180137 Trade/Device Name: AtriCure cryoice cryo-ablation probe (CRYO3), AtriCure
More informationThames Valley Priorities Committee Commissioning Policy Statement
Bracknell and Ascot Clinical Commissioning Group Slough Clinical Commissioning Group Windsor, Ascot and Maidenhead Clinical Commissioning Group Thames Valley Priorities Committee Commissioning Policy Statement
More informationVACAVILLE DERMATOLOGY
Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating
More informationSkin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry
Skin lesions The Good and the Bad Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry Case 1 32 year old woman Australian Lesion on back New hair growing
More informationMultiPulse PRO - CO 2 Laser -
MultiPulse PRO - CO 2 Laser - Specifications Laser: CO 2 RF-PSD, class 4 Wavelength: Power: Pulse duration: Pulse modes: Handpieces: Accessories*: Display: Dimensions: Weight: 10,600 nm Max. 40 W or Max.
More informationOur medtech experts are yours. 510(k)s for Connected Medical Devices.
Our medtech experts are yours. 510(k)s for Connected Medical Devices. David Amor, MSBE, CQA Principal, Medgineering david@medgineering.com www.medgineering.com Agenda. What is a 510(k)? How do we determine
More informationLow Priority Treatment Policies
Low Priority Treatment Policies Each position statement indicates whether the procedure is routinely funded or restricted by specific criteria. If the procedure is not routinely funded or outside of criteria,
More informationUltraPulse Encore. Bridge Therapy Fractional CO 2.
UltraPulse Encore Bridge Therapy Fractional CO 2 www.aesthetic.lumenis.com bridging the gap BRIDGE THERAPY Bridge Therapy is the family of fractional treatments encompassing PigmentFX, ActiveFX, DeepFX
More informationInstrument, Surgical, Powered, Laser 79-GEX 21I CFR878-48
kor~f ¼ UL 2 62004 This 510(K) Summary of safety and effectiveness for the Millennium Dental Technologies PerioLase Dental Laser System is submitted in accordance with the requirements of the SMDA 1990
More informationLumps and Bumps: The Dermatology of Lid Lesions
Lumps and Bumps: The Dermatology of Lid Lesions Thomas J. Joly, MD, PhD Assistant Professor of Ophthalmology Eastern Virginia Medical School Ophthalmic Plastic Surgery Service Virginia Eye Consultants
More informationDERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES
UNC DIVISION OF PLASTIC AND RECONSTRUCTIVE SURGERY DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES MEDICAL KNOWLEDGE A. Anatomy/Physiology/Embryology Goal: The resident will have knowledge
More informationIcon specifications. Handpiece compatibility
Icon specifications Voltage Frequency Max. power Speed Weight 90-264 VAC 50-60 Hz 1600 VA Up to 3 Hz (pulse rate) 104 lb. (47.1kg) Handpiece compatibility Handpiece Technologies Hair removal Pigmented
More informationCO 2 Laser Treatment Periocular Area. Prof. G.Cannarozzo
CO 2 Laser Treatment Periocular Area Prof. G.Cannarozzo Prof. G. Cannarozzo, M.D. Department of Dermatology University of Rome Tor Vergata - Italy Introduction The evolution of CO 2 laser systems has made
More informationReconstructive and Cosmetic Services
Reconstructive and Cosmetic Services Policy Number: 10.01.09 Last Review: 4/2018 Origination: 2/2006 Next Review: 4/2019 Policy Determination of whether a proposed therapy would be considered reconstructive
More informationJuly 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service July 10, 2015 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 X-spine
More informationGuidance for Industry and FDA Staff 510(k) Device Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device DRAFT GUIDANCE
Guidance for Industry and FDA Staff 510(k) Device Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device DRAFT GUIDANCE This guidance document is being distributed for comment
More informationUsing Recall Data to Assess the 510(k) Process
Using Recall Data to Assess the 510(k) Process Ralph F. Hall Distinguished Professor and Practitioner University of Minnesota Law School July 28, 2010 Acknowledgments 2 Disclosures 3 Agenda I. Research
More informationDraft Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: External Penile Rigidity Devices
Draft Guidance for Industry and FDA Staff Class II Special Controls Guidance Document: External Penile Rigidity Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationFebruary 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040
February 15, 2018 AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 Re: K180138 Trade/Device Name: AtriCure cryoice cryo-ablation probe (CRYO2) Regulation
More informationTELEMED. November 3, Engineering Manager Dariaus ir Gireno str. 42 Vilnius, LT LITHUANIA
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 TELEMED Engineering Manager
More informationTIMEDSURGERY DIRECT-MODE PROGRAMME DATA
Bipolar coagulation Direct Coag 4 50 Bipolar forceps Monopolar 8-10 of vessels macroelectrodes Comment: Recommended for haemostasis in microsurgery Coagulation of Direct Coag 50 or 72 EM 15 + forceps Monopolar
More informationMCL 30. MCL 30 Dermablate Fractional Er:YAG (with MICROSPOT EXTENSION SET) EN 1
MCL 30 MCL 30 Dermablate Fractional Er:YAG (with MICROSPOT EXTENSION SET) 1 The third generation of the Dermablate series MCL 29 Dermablate Dermablate D1 MCL 30 Dermablate MCL29, the first Er:YAG laser
More informationAcne Related Procedures ACNE RELATED PROCEDURES HS-258. Policy Number: HS-258. Original Effective Date: 9/4/2014. Revised Date(s): 6/8/2015
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationDERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY
DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationDiode and diode pumped frequencies doubled solid state. 940 nm, 532 nm
VariLite System Specifications Treatment Laser: Wavelengths: Diode and diode pumped frequencies doubled solid state 940 nm, 532 nm Energy Density: 940 nm: 900 J/cm 2 532 nm: 950 J/cm 2 Pulse Duration:
More informationFebruary 2, Dear Dr. Shuren,
American Cancer Society Cancer Action Network 555 11 th Street, NW Suite 300 Washington, DC 20004 202.661.5700 www.acscan.org Jeffrey E. Shuren, M.D., J.D. Director, Center for Devices and Radiological
More informationCommissioning Policy: Treatments Designed to Improve Aesthetic Appearance
Commissioning Policy: Treatments Designed to Improve Aesthetic Appearance Policy Statement: Coventry and Rugby CCG consider funding of treatments designed to improve aesthetic appearance to be of low priority
More informationQualifying for CNPBC Certification
MODULE OVERVIEW Module 6: Energy Based Devices Photorejuvenation & Electromagnetic Therapies (3-day) consists of didactic & live patient hands-on training and examinations. Module 6 is a comprehensive
More informationFDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions
FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions 23 January 2017 On December 27, 2016, the U.S. Food and Drug
More informationComments of the Patient, Consumer, and Public Health Coalition. Strengthening the Center for Devices and Radiological Health s 510(k) Review Process
March 19, 2010 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Comments of the Patient, Consumer, and Public Health Coalition on Strengthening
More informationJanuary 7, Dear Ms. Chung:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 January 7, 2015 Jeisys
More information510(k) SUMMARY. Bristol, PA President. PhysioFlow Q-Link. Classification Name: Impedance plethysmograph (21 CER 870.
KC140102 Page 1 of 3 510(k) SUMMARY FB121 This 5 10(k) summary is submitted in accordance with the requirements of SMDA 1990 and 21 CER 807.87 Establishment Relistration Number: 3005467960 Address of Manufacturer:
More information510(k) SUMMARY STATEMEMT. Mettler Traction Device, MTD 4000 OCT Mettler Electronics Corp South Claudina Street Anaheim, CA 92805
510(k) SUMMARY STATEMEMT OCT - 8 2009 Mettler Traction Device, MTD 4000 Submitter's Name: Address: Mettler Electronics Corp. 1333 South Claudina Street Anaheim, CA 92805 Telephone: 714-533-2221 x324 Fax:
More informationKo0 -t. Exhibit 2 MAY 3 0? 510 (K) Summay. Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209
Ko0 -t Exhibit 2 MAY 3 0? 510 (K) Summay Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209 Contact: Stephen Shulman Phone: 734-663-0132 Fax: 734-663-1306
More informationIndustry s Perspective on the Status of Medical Device Regulations. FUNDISA Workshop 09 & 10 Oct Anele Vutha SAMED Regulatory Committee
Industry s Perspective on the Status of Medical Device Regulations FUNDISA Workshop 09 & 10 Oct 2014 Anele Vutha SAMED Regulatory Committee Today s Topics: 1. Medical Device Definition - Differences 2.
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationNonpharmacologic Treatment of Rosacea Corporate Medical Policy
Nonpharmacologic Treatment of Rosacea Corporate Medical Policy File Name: Nonpharmacologic Treatment of Rosacea. File Code: UM.SURG.11 Last Review: 01/2019 Next Review: 01/2020 Effective Date: 04/01/2019
More informationCommon skin tumors. Benign Epidermal Tumors. Topic. Clinicopathologic Variants. Seborrheic keratoses
Common skin tumors Topic Benign epidermal tumors Skin cyst and adnexal neoplasms Other common skin tumor Common skin malignancy สมศ กด ต นร ตนากร 26/02/2015 Benign Epidermal Tumors Seborrheic keratosis
More informationBacterin International Incorporated Mr. Howard L. Schrayer 600 Cruiser Lane Belgrade, Montana August 18, 2015
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Bacterin International
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More information510(k) 21 Summary of Safety and Effectiveness
510(k) 21 Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirement of 21 CFR 807.92. Submitter's Identification:
More informationOverhauling The 510(k) Process
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Overhauling The 510(k) Process Law360, New York (August
More informationMedical - Combined Medical Devices Guideline
Medical - Combined Medical Devices Guideline V 2.0- EFFECTIVE: 1ST OF AUG 2016 Medical - Combined Medical Devices Guideline 1 2 Medical - Combined Medical Devices Guideline Title TABLE OF CONTENTS Definitions
More informationGlobal Harmonization Task Force SG3 Comments and Recommendations ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO and 13488
Page 1 of 6 Global Harmonization Task Force SG3 ISO/DIS 9001: 2000 and ISO/DIS 9000: 2000 And Revision of ISO 13485 and 13488 GENERAL COMMENTS The Global Harmonization Task Force Study Group Three (GHTF
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationThe Reprocessing of Single- Use Medical Devices; Regulations Coming to Europe? CleanMed Europe Malmo, Sweden 26 September 2012
1 The Reprocessing of Single- Use Medical Devices; Regulations Coming to Europe? CleanMed Europe Malmo, Sweden 26 September 2012 2 Topics to be Covered Introduction to AMDR Introduction to single-use medical
More informationLumps and Bumps: An Organized Approach to Diagnosis and Management. Disclosure. Introduction. References. Structure of Skin.
Lumps and Bumps: An Organized Approach to Diagnosis and Management Nothing to disclose Disclosure Tammy Pifer Than, MS, OD, FAAO Carl Vinson VAMC tammythan@bellsouth.net References Fitzpatrick's Color
More informationUWMC Roosevelt Clinic Rotation Goals 2011 Procedural Dermatology Fellowship Program 1
Procedural Dermatology Fellowship Objectives University of Washington Medical Center-Roosevelt Rotation The primary goal of the University of Washington rotation of the Procedural Dermatology fellowship
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationTOBACCO PRODUCT OR MEDICAL PRODUCT?
TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:
More informationSAMED Position: Reuse of SUDs
SAMED Position: Reuse of SUDs What We Will Cover SAMED - who we are and what we do Definition of single-use device Overview of single-use device reprocessing Overview of SA and other countries regulatory
More informationThames Valley Priorities Committee Commissioning Policy Statement
East Berkshire Clinical Commissioning Group Excluded: Procedure not routinely funded Thames Valley Priorities Committee Commissioning Policy Statement Policy No. TVPC16 Aesthetic treatments for adults
More informationKey CDRH Regulatory Initiatives
Key CDRH Regulatory Initiatives Revamping the Submission Process Creating New Strategies Ralph F. Hall University of Minnesota Law School Counsel Faegre Baker & Daniels May 8, 2012 Purpose of Today s Program
More informationSupplemental Appendix
Supplemental Appendix Appendix Table 1. Sub-Categorization of Medical Devices Included in Study Sample vel Medical Devices (N = 309) Cardiovascular Cardiac (ventricular) assist devices Cardiac prosthetic
More informationANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015
DEPARTMENT OF HEALTH & HUMAN SERVICES Silver Spring, MD 20993 ANDA 060851 Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY 10970 Docket No. FDA-2011-P-0081
More informationQuality Management System Certification. Understanding Quality Management System (QMS) certification
Quality Management System Certification Understanding Quality Management System (QMS) certification The medical device manufacturing sector is one of the most regulated sectors in which significant quality
More informationOver the Counter Hearing Aids:
Over the Counter Hearing Aids: A deeper dive into the OTC Hearing Aid Act of 2017 Michael Scholl Director of Government and Community Relations Director of Government and Community Relations OTC Legislation
More information